Hepatic Encephalopathy News and Research

RSS
Cognitive impairment may not be fully reversible in patients with liver disease: Study

Cognitive impairment may not be fully reversible in patients with liver disease: Study

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy

Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

First-of-its-kind patient, healthcare provider support program for management of HE

First-of-its-kind patient, healthcare provider support program for management of HE

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

54% of liver cirrhosis patients experience neurocognitive impairments

54% of liver cirrhosis patients experience neurocognitive impairments

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

Presence and type of cirrhosis complications are strong predictors of mortality: Study

Presence and type of cirrhosis complications are strong predictors of mortality: Study

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients

Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients

Cumberland Pharmaceuticals submits Acetadote sNDA for non-acetaminophen acute liver failure

Cumberland Pharmaceuticals submits Acetadote sNDA for non-acetaminophen acute liver failure

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Xifaxan drug receives FDA approval

Xifaxan drug receives FDA approval

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Patients with chronic hepatitis C can benefit by drinking coffee

Patients with chronic hepatitis C can benefit by drinking coffee

Higher rate of motor vehicle crashes in MHE patients

Higher rate of motor vehicle crashes in MHE patients